Identification and optimization of a novel series of indoleamine 2,3-dioxygenase inhibitors.

Bioorg Med Chem Lett

Oncology Biology, Bristol-Myers Squibb Research and Development, Princeton, NJ 08543-5400, United States.

Published: February 2017

The discovery of a series of structurally-novel biaryl urea IDO inhibitors is described. Optimization of a micromolar hit through iterative cycles of synthesis and screening in an assay measuring IDO-mediated intracellular conversion of tryptophan to kynurenine led to potent inhibitors with favorable selectivity and metabolic stability profiles.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2016.12.015DOI Listing

Publication Analysis

Top Keywords

identification optimization
4
optimization novel
4
novel series
4
series indoleamine
4
indoleamine 23-dioxygenase
4
23-dioxygenase inhibitors
4
inhibitors discovery
4
discovery series
4
series structurally-novel
4
structurally-novel biaryl
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!